Oncology
Lirafugratinib Expands FGFR2 Cholangiocarcinoma Options
The FDA approved lirafugratinib for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma harboring an eligible FGFR2 fusion or rearrangement.
Rayan Salih · September 30, 2026 · 7 min